Glaxo Agrees To $65M Settlement In Antitrust Suit Over Paxil Patent Gaming: Report
In a deal that closely resembles similar settlements for arthritis drug Relafen and prescription antibiotic Augmentin, GlaxoSmithKline has reportedly agreed to pay $65 million to settle a class action antitrust suit...To view the full article, register now.
Already a subscriber? Click here to view full article